Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with ...
Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...
GlobalData on MSN2d
Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMRIn Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.
There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.
Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...
who fell on his sword after the Aduhelm situation got so bad hospitals were refusing to let Biogen sales execs from entering the building. In fairness, Viehbacher received only $4m in 2023 ...
“Building upon the promising results from the ... its clinical development,” said Travis Murdoch, Head of HI-Bio at Biogen. “Losing a kidney after receiving a long-awaited transplant is ...
“Building upon the promising results from the ... its clinical development,” said Travis Murdoch, Head of HI-Bio at Biogen Losing a kidney after receiving a long-awaited transplant is ...
TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ETCompany ParticipantsChris Viehbacher - CEOConference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback